To the best of our knowledge, this study is the first to demonstrate the protective effects of pemafibrate, a novel selective PPARα modulator, against UUO‐induced CKD by attenuating the inflammatory and EMT responses via FGF21‐ and BHB‐dependent mechanisms (Figure 4d). Here, FGF21 is linked to chronic kidney disease.